Venous Leg Ulcers (Crural ulcer) (Dermatology) - Drugs in Development, 2021

March 2021 | 79 pages | ID: V8EABDAD2BF5EN
Global Markets Direct

Abstracts

Venous Leg Ulcers (Crural ulcer) (Dermatology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers - Drugs in Development, 2021, provides an overview of the Venous Leg Ulcers (Dermatology) pipeline landscape.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Venous Leg Ulcers (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural Ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Unknown stages are 1, 1, 9, 2, 4 and 1 respectively.

Venous Leg Ulcers (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Dermatology).
• The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Venous Leg Ulcers (Dermatology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Venous Leg Ulcers (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Dermatology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Dermatology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Venous Leg Ulcers (Dermatology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Venous Leg Ulcers (Crural Ulcer) - Overview
Venous Leg Ulcers (Crural Ulcer) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Venous Leg Ulcers (Crural Ulcer) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Venous Leg Ulcers (Crural Ulcer) - Companies Involved in Therapeutics Development
Aurealis Therapeutics AG
CytoTools AG
Energenesis Biomedical Co Ltd
GangaGen Biotechnologies Pvt Ltd
Hypo-Stream Ltd
Ilkos Therapeutics Inc
Mallinckrodt Plc
MediWound Ltd
NovaLead Pharma Pvt Ltd
Promore Pharma AB
QBiotics Pty Ltd
Reponex Pharmaceuticals Aps
RHEACELL GmbH & Co KG
Venturis Therapeutics Inc
Zhittya Genesis Medicine Inc
Venous Leg Ulcers (Crural Ulcer) - Drug Profiles
Amesanar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUP-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVBT-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVBT-141B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diperoxochloric acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBC-1013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENERGIF-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EscharEx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EscharEx Second Generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FGF-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLP-328 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropocamptide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-42909 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Venous Leg Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects
Venous Leg Ulcers (Crural Ulcer) - Discontinued Products
Venous Leg Ulcers (Crural Ulcer) - Product Development Milestones
Featured News & Press Releases
Jan 11, 2021: MediWound provides progress update on its EscharEx clinical development program
Oct 08, 2020: The IND application of ENERGI-F703 for treating venous leg ulcers (VLU) has been approved by TFDA
Jul 14, 2020: Promore Pharma is granted a patent for ropocamptide in the US
Mar 24, 2020: Promore Pharma reached the targeted number of patients completing treatment in the HEAL LL-37 Phase IIb clinical trial
Dec 10, 2019: Promore Pharma has finalized recruitment of patients in HEAL LL-37 early
Dec 03, 2019: MediWound Initiates U.S. Phase 2 Adaptive design study of EscharEx for treatment of Venous Leg Ulcers
Aug 27, 2019: Promore Pharma is granted a patent for LL-37 in Japan
Jul 22, 2019: MediWound launches EscharEx U.S. clinical development program
Jun 20, 2019: Promore Pharma has recruited half of the patients in HEAL LL-37
Oct 01, 2018: Promore Pharma has enrolled first patient in HEAL LL-37 in Poland
Sep 06, 2018: Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland
Aug 22, 2018: Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland
Jul 03, 2018: Promore Pharma receives approval for Phase IIb trial with LL-37
Oct 31, 2017: Promore Pharma Signs Agreement with CRO PCG Clinical Services
Sep 21, 2017: Promore Pharma Signs Manufacturing Agreement with APL
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Aurealis Therapeutics AG, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by CytoTools AG, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Energenesis Biomedical Co Ltd, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by GangaGen Biotechnologies Pvt Ltd, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Hypo-Stream Ltd, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Ilkos Therapeutics Inc, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Mallinckrodt Plc, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by MediWound Ltd, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Promore Pharma AB, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by QBiotics Pty Ltd, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Reponex Pharmaceuticals Aps, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by RHEACELL GmbH & Co KG, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Venturis Therapeutics Inc, 2021
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Zhittya Genesis Medicine Inc, 2021
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects, 2021
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects, 2021 (Contd..1)
Venous Leg Ulcers (Crural Ulcer) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021